ENGLEWOOD, Colo., Aug. 12, 2021 /PRNewswire/ -- Ampio
Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical
company focused on the advancement of immunology-based therapies
for prevalent inflammatory conditions for which there are limited
treatment options, reminds stockholders to vote on the proposals
listed in the Company's proxy statement in advance of its upcoming
annual meeting.
Stockholders of record as of the close of business on
June 21, 2021 (the "Record Date")
should have previously received proxy materials in connection with
Ampio's 2021 Annual Meeting of Stockholders (the "Annual
Meeting"). As set forth in the proxy materials, the Annual
Meeting will be conducted as a virtual meeting via a live webcast
on Saturday, August 14, 2021 at
9:00 a.m. (MT) with online access to
the meeting beginning at 8:45 a.m.
(MT). Only stockholders of record and beneficial owners of
shares of Ampio Pharmaceuticals common stock as of the close of
business on the Record Date, may vote and ask questions during the
Annual Meeting. Others may join the Annual Meeting as a guest;
however, guests will not have the opportunity to vote or ask
questions.
The Annual Meeting date was previously disclosed in the
Company's Form 10-Q, Item 5. "Other Information" on May 5, 2021 and also disclosed on the Company's
proxy statement, which was mailed out to stockholders as of the
Record Date on or around June 30,
2021.
In order to attend the Annual Meeting as a stockholder, you must
have the information printed in the proxy materials and then
proceed to register at www.virtualshareholdermeeting.com/AMPE2021.
As part of the registration process, you must enter the 16-digit
control number located on your proxy card, voting instruction form,
or Notice of Internet Availability. Guests are not required to
enter a 16-digit control number.
We urge all stockholders to vote in advance of the Annual
Meeting by using one of the methods described in the proxy
materials for the Annual Meeting to ensure that your shares are
represented.
The Board of Directors and management of Ampio Pharmaceuticals,
Inc. appreciate the support and thanks its stockholders for their
investment in Ampio Pharmaceuticals.
An audio replay of the annual meeting will be posted on the
Company's website within 24 hours of the meeting
(https://ampiopharma.com/investors/presentations-media).
About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. is a biopharmaceutical company
primarily focused on the advancement of immunology-based therapies
to treat prevalent inflammatory conditions for which there are
limited treatment options. Ampio's lead drug, Ampion™, is backed by
an extensive patent portfolio with intellectual property protection
extending through 2037 and will be eligible for 12-year FDA market
exclusivity upon approval as a novel biologic under the Biologics
Price Competition and Innovation Act (BPCIA).
Forward Looking Statements
Ampio's statements in this press release that are not historical
fact, and that relate to future plans or events, are
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by the use of words such as "could,"
"believe," "expect," "plan," "anticipate," and similar expressions.
These forward-looking statements include statements regarding
Ampio's ability to access equity financing and fund research and
development programs and operations through the fourth quarter of
2022, expectations with respect to Ampion, including its ability to
treat prevalent inflammatory conditions for which there are limited
treatment options (including COVID-19) and its ability to offer the
benefits of steroids without the side effects, the significance of
reported results in early clinical trials, the timing of patient
enrollment for the Phase I Long-COVID trial and the Phase II
COVID-19 trials, the timing and outcome of the Company's
application for Emergency Use Authorization of Ampion in COVID-19
patients with inhalation and intravenous routes of drug delivery,
the term of Ampion's patent protection and the timing and
likelihood of Ampion's approval as a novel biologic under the
BPCIA, including the availability of 12-year FDA market exclusivity
in connection with such approval. These forward-looking statements
are made on the basis of the current beliefs, expectations, and
assumptions of the management of Ampio and are subject to
significant risks and uncertainties that could cause actual results
to differ materially from what may be expressed or implied in these
forward-looking statements. The risks and uncertainties involved
include those detailed from time to time in Ampio's filings with
the Securities and Exchange Commission, including without
limitation, in Ampio's Annual Report on Form 10-K and other
documents filed with the Securities and Exchange Commission. Ampio
undertakes no obligation to revise or update these forward-looking
statements, whether as a result of new information, future events
or otherwise.
Media Contact
Katie Kennedy
katie@gregoryfca.com
610-731-1045
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ampio-pharmaceuticals-reminds-stockholders-to-vote-shares-in-advance-of-2021-annual-meeting-301354092.html
SOURCE Ampio Pharmaceuticals, Inc.